UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 96.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 958,671 shares of the biopharmaceutical company's stock after purchasing an additional 471,902 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.32% of Amicus Therapeutics worth $9,031,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Virtus Fund Advisers LLC purchased a new stake in shares of Amicus Therapeutics during the 4th quarter worth $29,000. Covestor Ltd increased its position in shares of Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 2,312 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Amicus Therapeutics in the fourth quarter valued at approximately $79,000. KBC Group NV boosted its stake in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after acquiring an additional 3,120 shares during the last quarter. Finally, Sciencast Management LP acquired a new position in Amicus Therapeutics during the fourth quarter worth $100,000.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD traded down $0.16 on Wednesday, hitting $6.10. The company's stock had a trading volume of 4,522,170 shares, compared to its average volume of 2,910,781. The firm has a market capitalization of $1.88 billion, a P/E ratio of -33.89, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a one year low of $5.81 and a one year high of $12.65. The stock has a fifty day moving average of $6.69 and a two-hundred day moving average of $8.50.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on FOLD. UBS Group upped their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company decreased their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. Finally, The Goldman Sachs Group cut their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Amicus Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.